Research · Sep 3, 2026
[A] Agilent Technologies Thesis 2026: McDonnell Reset Tests Biotech Funding Recovery
Agilent Technologies Inc. FY2025 revenue ~$6.5-6.7B (+0-3%) with adj. EPS ~$5.30-5.50 reflecting continued biotech funding environment cyclical pressure (post-2021 boom selected funding compression) + selected China weakness + selected operational discipline + selected pricing partially offset by selected services + consumables recurring revenue stability. Leading global life sciences + diagnostics instruments + applied chemistry company; spun off from Hewlett-Packard November 1999 (selected as test + measurement business). Headquartered in Santa Clara California. 3 segments: Life Sciences & Applied Markets Group (LSAG) ~53% ($3.5B — liquid chromatography LC + mass spectrometry MS + selected gas chromatography + selected applied markets pharma/biotech/chemical/food/environmental) + Agilent CrossLab Group (ACG) ~26% ($1.7B — services + consumables; selected recurring + high-margin 25-30%) + Diagnostics & Genomics Group (DGG) ~21% ($1.3B — pathology Dako acquired 2012 + genomics + nucleic acid). CEO Padraig McDonnell since May 1, 2024 (succeeded Mike McMullen CEO 2015-2024 who became Executive Chair; McDonnell ex-Agilent ACG President; ~25-year Agilent career). McDonnell tenure executed continued operational excellence + selected operational reset + selected pricing discipline + selected China navigation + selected biotech funding cycle navigation. ~30,000+ customers globally. ~15-20% China revenue exposure with selected pharma R&D capex weakness FY2023-2025. Capital return: dividend $0.99-1.02/share + buybacks $500M-1B; net debt $2-3B; A3/A- investment grade. FY2026 thesis: McDonnell operational reset + biotech funding recovery + ACG recurring revenue stability + capital return. Risks: biotech funding cycle, China demand, pharma R&D cycle.